Lupin Teams Up with Spektus Pharma to Launch DeslaFlex in Canada

Lupin shares rose 1.55% to Rs 2,254.95 after the company announced a licence and supply agreement with Spektus Pharma to bring the innovative antidepressant DeslaFlex to the Canadian market.

 DeslaFlex, developed by Spektus using its proprietary Flexitab oral drug-delivery platform, offers a novel approach to treating Major Depressive Disorder.

The strategic partnership leverages Lupin's strong commercial presence in Canada and Spektus's expertise in creating differentiated, novel formulations. This collaboration aims to successfully introduce DeslaFlex and build a platform for future launches, further strengthening Lupin's CNS portfolio with physician-endorsed therapies aligned with supportive regulatory frameworks.

Also Read: Role of Wellness in Corporate & Community Health

Claus Jepsen, President, Global Specialty at Lupin, stated, "This milestone reinforces our long-term commitment to advancing Lupin's CNS footprint and deepens our commitment to Canadian healthcare. The addition of DeslaFlex to our portfolio provides patients and clinicians with much-needed flexibility in the management of Major Depressive Disorder, enabling clinicians to deliver more personalized, patient-focused care."

Zarvaan Merchant, CEO of Spektus Pharma, added, "This partnership with Lupin represents a key milestone as Spektus transitions from development to commercial execution. Lupin's global brand and established commercial strength in Canada make it an ideal partner to realize the full value of DeslaFlex for patients across this important market."

Lupin, a global pharmaceutical leader headquartered in Mumbai, India, distributes products in over 100 markets and specializes in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company also reported a 37.46% rise in consolidated net profit to Rs 1,175.55 crore in Q3 FY26, with total revenue from operations climbing 24.26% year-on-year to Rs 7,167.52 crore for the quarter ending December 31, 2025.